Plant Name: Thespesia populnea
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0051434; BH3 domain binding | 8.058E-09 | 1.755E-04 | BCL2, BCL2L1, MCL1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.911E-08 | 4.198E-04 | AKR1B1, ALOX12, ALOX15, CYP2C19, GAA, HSD17B10, KDM4E, LDHA, LDHB |
| BP | GO:0008152; metabolic process | GO:0006089; lactate metabolic process | 1.325E-07 | 4.808E-04 | HIF1A, LDHA, LDHB |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 5.231E-07 | 1.424E-03 | BCL2, BCL2L1, MCL1, POLB |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 9.167E-07 | 1.663E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 9.167E-07 | 1.663E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.011E-06 | 3.128E-03 | BCL2, BCL2L1, HIF1A, MCL1 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.748E-06 | 3.559E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.748E-06 | 3.559E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 4.736E-06 | 4.465E-03 | BCL2, BCL2L1, MCL1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 9.151E-06 | 6.227E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004459; L-lactate dehydrogenase activity | 9.151E-06 | 6.227E-03 | LDHA, LDHB |
| CC | GO:0032991; macromolecular complex | GO:0097136; Bcl-2 family protein complex | 1.372E-05 | 7.297E-03 | BCL2L1, MCL1 |
| BP | GO:0008152; metabolic process | GO:0019369; arachidonic acid metabolic process | 1.939E-05 | 8.983E-03 | ALOX12, ALOX15, CYP2C19 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 1.939E-05 | 8.983E-03 | BCL2, BCL2L1, POLB |
| BP | GO:0009987; cellular process | GO:2001244; positive regulation of intrinsic apoptotic signaling pathway | 2.164E-05 | 9.425E-03 | BCL2, BCL2L1, MCL1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 8.661E-06 | 2.685E-04 | LDHB; LDHA; GAA; ALOX15; AKR1B1; ALOX12; CYP2C19; HSD17B10 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.216E-06 | 2.685E-04 | LMNA; BCL2; BCL2L1; MCL1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.653E-05 | 5.484E-04 | ALOX15; ALOX12; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.211E-04 | 1.876E-03 | LDHA; BCL2; HIF1A |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.552E-04 | 1.924E-03 | ALOX15; ALOX12; CYP2C19 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.271E-04 | 2.750E-03 | BCL2; BCL2L1; MCL1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.419E-04 | 2.750E-03 | ALOX15; CYP2C19 |
| hsa00640 | Propanoate metabolism_Homo sapiens_hsa00640 | 4.170E-04 | 2.750E-03 | LDHB; LDHA |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.661E-04 | 2.750E-03 | GAA; AKR1B1 |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 6.527E-04 | 3.679E-03 | LDHB; LDHA |
| hsa00010 | Glycolysis / Gluconeogenesis_Homo sapiens_hsa00010 | 1.822E-03 | 7.532E-03 | LDHB; LDHA |
| hsa00270 | Cysteine and methionine metabolism_Homo sapiens_hsa00270 | 8.261E-04 | 4.268E-03 | LDHB; LDHA |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 1.060E-03 | 5.057E-03 | BCL2; BCL2L1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.887E-03 | 1.266E-02 | BCL2; BCL2L1; MCL1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.822E-03 | 7.532E-03 | LDHA; HIF1A |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.436E-04 | 2.750E-03 | POLB; MPG |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.980E-03 | 1.087E-02 | BCL2; BCL2L1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.043E-03 | 7.918E-03 | SLCO1B1; SLCO1B3 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.939E-03 | 1.601E-02 | BCL2; HIF1A; BCL2L1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 4.083E-03 | 1.266E-02 | LDHB; LDHA |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.474E-03 | 1.197E-02 | BCL2; BCL2L1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.527E-03 | 1.558E-02 | BCL2; BCL2L1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.527E-03 | 1.558E-02 | ESR1; HIF1A |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.565E-02 | 4.043E-02 | HIF1A; ESR1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| C00-D49: Neoplasms | Relapsed or refractory chronic lymphocytic leukemia | NA | BCL2L1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | BCL2L1; HIF1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Lymphoid malignancies | NA | BCL2L1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; ESR1; ESR1 |
| C00-D49: Neoplasms | Advanced small cell lung cancer | NA | BCL2L1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | BCL2; BCL2; MCL1; BCL2L1; ESR1; ESR1; HIF1A |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |